Ann: PTX-100 receives U.S. FDA Fast Track Designation, page-51

PTX is way undervalued and with recent announcements and presentations, PTX needs to be re-evaluated by investors, brokers and especially fund managers which should see a major rerating. When you compare peers at a comparable status, it will substantiate this major rerate. PTX seems to be just starting to get this rerate happening. I look forward to seeing how they do this. Miles Prince needs to be a key speaker to brokers and fund managers and this new milestone and his enthusiasm will kick goals. DYOR!!!!